Actelion's Macitentan Meets Primary Endpoint In Pivotal SERAPHIN Study, Approval Filings Expected In Fourth Quarter

Swiss biotech Actelion expects to submit its next-generation PAH therapy macitentan for approval in the fourth quarter of this year, giving it time to replace current top-selling product Tracleer before that product loses patent protection in 2015.